MedPath

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Phase 3
Suspended
Conditions
Candidiasis, Invasive
Candidemia
Interventions
Registration Number
NCT05178862
Lead Sponsor
Scynexis, Inc.
Brief Summary

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

Detailed Description

Not available

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
220
Inclusion Criteria
  • Subject is a male or female adult ≥ 18 years of age on the day the study informed consent is signed.
  • Subject has a diagnosis of candidemia and/or invasive candidiasis, defined as evidence of Candida spp in either a bloodstream or tissue culture from a normally sterile site (excluding eye, cardiac tissue, bone tissue, central nervous system or prosthetic device) collected ≤ 4 days (within 96 hours) prior to initiation of IV echinocandin accompanied by any related clinical signs and/or symptoms (e.g., fever [on one occasion > 38°C], hypotension, or local signs of inflammation).

Key

Exclusion Criteria
  • Subject has any of the following forms of invasive candidiasis at Screening:

    • Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed),
    • Osteomyelitis,
    • Endocarditis or myocarditis,
    • Meningitis, endophthalmitis, or any central nervous system infection,
    • Chronic disseminated candidiasis,
    • Urinary tract candidiasis due to ascending Candida infection secondary to unresolved obstruction or non-removeable device in the urinary tract,
    • Patients with a sole diagnosis of mucocutaneous candidiasis, i.e., oropharyngeal, esophageal, or genital candidiasis; or Candida lower urinary tract infection or Candida isolated solely from respiratory tract specimens,
    • Patients with concurrent invasive fungal infection other than Candida spp., e.g., cryptococcosis, mold infection or endemic fungal infection,
    • Patients who failed a previous antifungal therapy for the same infection,
    • Subject has an inappropriately controlled fungal disease source (e.g., indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained) that is likely to be the source of the candidemia or invasive candidiasis.
  • Subject has abnormal liver test parameters: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels > 10-fold the upper limit of normal (ULN).

  • Subject has severe hepatic impairment and a history of chronic cirrhosis (Child-Pugh score > 9).

  • Subject has received more than 48 hours of non-echinocandin antifungal therapy for the treatment of invasive candidiasis (including candidemia) within 96 hours preceding initiation of IV echinocandin.

    o Exception: Receipt of antifungal therapy to which any Candida spp. isolated in qualifying culture is not susceptible.

  • Baseline QTcF ≥ 500 msec.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IV echinocandin followed by oral ibrexafungerp (SCY-078)SCY-078-
IV echinocandin followed by oral ibrexafungerp (SCY-078)Echinocandin-
IV echinocandin followed by oral fluconazoleFluconazole-
IV echinocandin followed by oral fluconazoleEchinocandin-
Primary Outcome Measures
NameTimeMethod
Global Response at End of Treatment (EU European Medicines Agency [EMA] Only)Up to 6 weeks

The percentage of subjects with Successful Global Response, as determined by the Data Review Committee

All-cause mortality (US FDA Only)Day 30

The number and percentage of subjects in each treatment group who are alive and deceased in the ITT population.

Secondary Outcome Measures
NameTimeMethod
Global Response at Day 14Day 14

The percentage of subjects with Successful Global Response, as determined by the Data Review Committee

Trial Locations

Locations (72)

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Saint Luc University Hospital

🇧🇪

Brussels, Belgium

University Hospitals Leuven, Campus Gasthuisberg

🇧🇪

Leuven, Belgium

Mediclinic Victoria

🇿🇦

Tongaat, KwaZulu-Natal, South Africa

Duke University

🇺🇸

Durham, North Carolina, United States

University of Maryland Medical Center

🇺🇸

Baltimore, Maryland, United States

Johns Hopkins Hospital

🇺🇸

Baltimore, Maryland, United States

Banner University Medical Center-Tucson

🇺🇸

Tucson, Arizona, United States

Augusta University Medical Center

🇺🇸

Augusta, Georgia, United States

Ochsner Medical Center

🇺🇸

New Orleans, Louisiana, United States

Mercury Street Medical Group, PLLC

🇺🇸

Butte, Montana, United States

University of Pennsylvania School of Medicine

🇺🇸

Philadelphia, Pennsylvania, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

LAIKO General Hospital

🇬🇷

Athens, Greece

University Health Network- Toronto General Hospital

🇨🇦

Toronto, Ontario, Canada

University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv", Plovdiv, Department of Surgery

🇧🇬

Plovdiv, Bulgaria

Paris University Hospitals Center- Cochin Hospital

🇫🇷

Paris, France

University Multiprofile Hospital for Active Treatment "Prof. Dr. Stoyan Kirkovich"

🇧🇬

Stara Zagora, Bulgaria

Princess Margaret Hospital

🇨🇦

Toronto, Ontario, Canada

University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov", Sofia, Clinic of Purulent-Septic Surgery

🇧🇬

Sofia, Bulgaria

University Hospital Center of Poitiers

🇫🇷

Poitiers, France

Rambam Health Care Campus, Institute of Infectious Diseases

🇮🇱

Haifa, Israel

McGill University Health Centre

🇨🇦

Montréal, Quebec, Canada

Lady Davis Carmel Medical Center, Infectious Diseases Unit

🇮🇱

Haifa, Israel

IRCCS- University Hospital San Martino-IST

🇮🇹

Genoa, Liguria, Italy

Big Metropolitan Hospital Niguarda Regional Health Authority

🇮🇹

Milan, Italy

University Polyclinic Hospital of Modena

🇮🇹

Modena, Italy

Central Friuli University Healthcare Company

🇮🇹

Udine, Italy

University Hospital de La Princesa

🇪🇸

Madrid, Spain

University Clinical Hospital of Valencia

🇪🇸

Valencia, Spain

LSU Health Sciences Center

🇺🇸

Shreveport, Louisiana, United States

University of Minnesota Medical Center

🇺🇸

Minneapolis, Minnesota, United States

University of Texas Health Science Center at Houston

🇺🇸

Houston, Texas, United States

The Miriam Hospital

🇺🇸

Providence, Rhode Island, United States

University Hospital Ghent

🇧🇪

Ghent, Belgium

Nantes University Hospital Center

🇫🇷

Nantes, France

Victor Dupouy Hospital Center Argenteuil

🇫🇷

Argenteuil, France

University Hospital Freiburg

🇩🇪

Freiburg, Baden-Wuerttemberg, Germany

Saint-Louis Hospital

🇫🇷

Paris, France

Univeristy Hospital Jena

🇩🇪

Jena, Thuringia, Germany

University Hospital Cologne

🇩🇪

Cologne, Germany

Frankfurt University Clinic

🇩🇪

Frankfurt, Germany

Municipal Hospital Munich GMbH/Hospital Neuperlach

🇩🇪

Munich, Germany

Helios Clinic Wuppertal

🇩🇪

Wuppertal, Germany

General Hospital of Athens "Evangelismos", 1st Department of Critical Care

🇬🇷

Athens, Greece

University General Hospital "Attikon"

🇬🇷

Athens, Greece

General Hospital of Athens "Evangelismos"

🇬🇷

Athens, Greece

General Hospital of Thessaloniki "Ippokratio"

🇬🇷

Thessaloníki, Greece

CHA Bundang Medical Center, CHA University

🇰🇷

Gyeonggi-do, Korea, Republic of

Chaim Sheba Medical Center

🇮🇱

Tel HaShomer, Israel

Keimyung University - Dongsan Medical Center

🇰🇷

Daegu, Korea, Republic of

Gangnam Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Zuid-Afrikaans Hospital

🇿🇦

Pretoria, Gauteng, South Africa

Netcare Jakaranda Hospital

🇿🇦

Pretoria, Gauteng, South Africa

Lakeview Hospital

🇿🇦

Benoni, Gauteng, South Africa

Wonju Severance Christian Hospital

🇰🇷

Wŏnju, Korea, Republic of

Life Groenkloof Hospital

🇿🇦

Pretoria, Gauteng, South Africa

FCRN Clinical Trials Centre

🇿🇦

Vereeniging, Gauteng, South Africa

Hospital del Mar Medical Research Institute (IMIM)

🇪🇸

Barcelona, Catalonia, Spain

University and Polytechnic Hospital La Fe

🇪🇸

Valencia, Spain

General University Hospital Gregorio Maranon

🇪🇸

Madrid, Spain

University of Pretoria and Steve Biko Academic Hospital

🇿🇦

Pretoria, South Africa

University Hospital Virgen Macarena

🇪🇸

Seville, Andalusia, Spain

University Hospital Puerta de Hierro Majadahonda

🇪🇸

Madrid, Spain

University of Alabama at Birmingham School of Medicine

🇺🇸

Birmingham, Alabama, United States

UC Davis Medical Center

🇺🇸

Sacramento, California, United States

University of Michigan Hospital

🇺🇸

Ann Arbor, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Mayo Clinic - Rochester

🇺🇸

Rochester, Minnesota, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath